Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study

Lookup NU author(s): Dr George KourounisORCiD, Dr Sam Tingle, Emily Thompson, Dr Ruth Owen, Professor James ShawORCiD, Steven White, Colin Wilson

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Copyright © 2025 Kourounis, Tingle, Maillo-Nieto, Wroe, Thompson, Owen, van Leeuwen, Holzner, Wadhera, Zeeshan Akhtar, Florman, Shaw, White and Wilson.Understanding which factors shape long-term pancreas graft outcomes after the critical first year post-transplantation is an ongoing challenge. This study assesses one-year HbA1c as a predictor of subsequent pancreas graft survival. A retrospective cohort study was conducted using the UNOS registry on all simultaneous pancreas-kidney (SPK) transplants between 2017 and 2023. Regression models with multiple imputations for missing data were used to evaluate predictors of long-term function. Non-linear relationships were modelled with restricted cubic splines (RCS). Among 2,917 SPK recipients (median follow-up 44 months, IQR: 25–60), one-year HbA1c was the strongest independent predictor of long-term graft survival. An HbA1c of 6.8% versus 4.4% (95th vs. 5th percentile) was associated with significantly worse graft survival (aHR = 2.48, 95% CI: 1.72–3.58). Simulated trial sample size calculations found that detecting a statistically and clinically significant reduction in one-year HbA1c from 7% to 6.5% would require 65 patients per group, whereas detecting a reduction in one-year graft loss from 12% to 9% would require 1,631 patients per group. HbA1c at 1 year is a robust, continuous marker of long-term graft function and may serve as a feasible, objective surrogate endpoint in future clinical trials, enabling smaller, more efficient study designs to evaluate interventions.


Publication metadata

Author(s): Kourounis G, Tingle SJ, Maillo-Nieto A, Wroe C, Thompson ER, Owen R, van Leeuwen L, Holzner M, Wadhera V, Zeeshan Akhtar M, Florman S, Shaw J, White S, Wilson C

Publication type: Article

Publication status: Published

Journal: Transplant International

Year: 2025

Volume: 38

Online publication date: 06/08/2025

Acceptance date: 22/07/2025

Date deposited: 03/09/2025

ISSN (print): 0934-0874

ISSN (electronic): 1432-2277

Publisher: Frontiers Media SA

URL: https://doi.org/10.3389/ti.2025.14940

DOI: 10.3389/ti.2025.14940

Data Access Statement: The data analyzed in this study is subject to the following licenses/ restrictions: The data that support the findings of this study are available from UNOS upon reasonable request. Requests to access these datasets should be directed to https://optn.transplant.hrsa. gov/data/view-data-reports/request-data/


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Kidney Research UK
National Institute for Health and Care Research (NIHR)
MRC
MRC/Y000676/1
Transplant Research Unit in Organ Donation and Transplantation (NIHR203332)

Share